EU SmPC
Medical Information
Roche COVID-19 Response  | Questions About Our Medicines? Visit medinfo.roche.com
307616@2x

Erlotinib plus bevacizumab combination studies

Erlotinib plus bevacizumab is a clinical guideline-recommended first-line treatment option for EGFR Mut+ NSCLC.1

Bevacizumab is an anti-VEGF monoclonal antibody that inhibits tumour growth by inhibiting new and recurrent tumour vessel growth.2

page_19_1@2x

Bevacizumab also reduces tumour size by regressing existing tumour vasculature.2-4

page_19_2@2x

Please click below for more information on the key clinical trials that demonstrate
erlotinib plus bevacizumab’s favourable efficacy and safety profile in the first-line treatment of EGFR Mut+ NSCLC.

Please note; in some countries the combination of erlotinib plus bevacizumab may not be registered or reimbursed